Statement: FDA Must Reject Tanezumab as a Treatment for Osteoarthritis Due to Unacceptable Dangers, Little to No Benefit
Undemocratic WTO Processes Produce Shameful Result on Intellectual Property and Covid at 12th WTO Ministerial
Letter to HHS Regarding OHRP Failure to Investigate Unethical Placebo-Controlled Trials of Indacaterol Maleate (Arcapta Neohaler) April 28, 2011
Comments on FDA Draft Guidance for Industry – Drug-Induced Liver Injury: Premarketing Clinical Evaluation December 24, 2007